Primary effusion lymphoma

Extranodal Lymphomas: Pathology and Management

Volumn , Issue , 2008, Pages 299-305

  Conconi, Annarita ^a   Carbone, Antonino ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056558964     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (61)

1. Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera, Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possibile pathogenetic role of the Epstein-Barr virus. Blood 1989; 73: 792-9.
2. Banks PM, Warnke RA. Primary effusion lymphoma. In: Jaffe, ES, Harris NL, Stein H, Vardiman JW, eds, World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haema - topoietic and Lymphoid Tissues, Lyon: International Agency for Research on Cancer Press, 2001: 260-3.
3. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood 2006; 107: 13-20.
4. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion Lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21: 3948-54.
5. Dotti G, Fiocchi R, Motta T, et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999; 13: 664-70.
6. Jones D, Ballestas M, Kaye KM, et al. Primary-effusion lymphoma and Kaposi’s sarcoma in a cardiactransplant recipient. N Eng J Med 1998; 339: 444-9.
7. Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus-8 associated lymphoproliferative disorder and Kaposi’s sarcoma. Br J Haematol 2001; 113: 425-8.
8. Ascoli V, Scalzo CC, Danese C, et al. Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men. Eur Respir J 1999; 14: 1231-4.
9. Boulanger E, Hermine O, Fermand JP, et al. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-negative elderly patients. Am J Hematol 2004; 76: 88-91.
10. Carbone A, Gloghini A, Vaccher E, et al. Kaposi’s sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 1996; 94: 533-43.
11. Gaidano G, Carbone A. Primary effusion lymphoma:a liquid phase lymphoma of fluid-filled body cavities. Adv Cancer Res 2001; 80: 115-46.
12. Renne R, Barry C, Dittmer D, et al. Modulation of cellular and viral gene expression by the latencyassociated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Virol 2001; 75: 458-68.
13. Matta H, Chaudhary PM. Activation of alternative NF-B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1--converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA 2004; 101: 9399-404.
14. Sarid R, Sato T, Bohenzky RA, Russo JJ, Chan Y. Kaposi’s sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3: 293-8.
15. McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 2005; 307: 739-41.
16. Li M, Lee H, Yoon DW, et al. Kaposi’s sarcomaassociated herpesvirus encodes a functional cyclin. J Virol 1997; 71: 1984-91.
17. Carbone A, Gloghini A, Bontempo D, et al. Proliferation in HHV-8-positive primary effusion lymphoma is associated with expression of HHV-8 cyclin but independent of p21(kip1). Am J Pathol 2000; 156: 1209-15.
18. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and inhibitory functions of KSHV-encoded chemokines. Science 1997; 278: 290-4.
19. Cannon M, Cesarman E, Boshoff C. KSHV Gprotein- coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2. Blood 2006; 107: 277-84.
20. Cesarman E. The role of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Recent Results Cancer Res 2002; 159: 27-37.
21. Gao SJ, Boshoff C, Jayachandra S, et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997; 15: 1979-85.
22. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 281-92.
23. Fassone L, Bhatia K, Gutierrez M, et al. Molecular profile of Epstein-Barr virus infection in HHV-8- positive primary effusion lymphoma. Leukemia 2000; 14: 271-7.
24. Hamoudi R, Diss TC, Oksenhendler E, et al. Distinct cellular origins of primary effusion lymphoma with and without EBV infection. Leuk Res 2004; 28: 333-8.
25. Fan W, Bubman D, Chadburn A, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 2005; 79: 1244-51.
26. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N Engl J Med 1995; 332: 1186-91.
27. Nador, RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 1996; 88: 645-56.
28. Gaidano G, Capello D, Cilia AM, et al. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. Genes Chromosomes. Cancer 1999; 24: 16-23.
29. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma, Blood 2003; 102: 1833-41.
30. Gaidano G, Capello D, Fassone L, et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol 2000; 16: 215-24.
31. Boulanger E, Agbalika F, Maarek O, et al. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J 2001; 2: 172-9.
32. Jenner RG, Maillard K, Cattini N, et al, Kaposi’s sarcoma- associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA 2003; 100: 10399-404.
33. Carbone A, Gloghini A. HHV-8-associated lymphoma:state-of-the-art review. Acta Haematol 2006; 117: 129-31.
34. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-80.
35. Carbone A, Gloghini A, Vaccher E, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphoma. A tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005; 7: 17-27.
36. Conconi A, Spina M, Ascoli V, et al. An IELSG international survey on primary effusion lymphoma (PEL). Blood 2004; 104: 3265 (abstract).
37. Ansari MQ, Dawson DB, Nador R, et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996; 105: 221-9.
38. Gaidano G, Gloghini A, Gattei V, et al. Association of Kaposi’s sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen, Blood 1997; 90: 4894-900.
39. Gaidano G, Capello D, Gloghini A. BCL-6 in AIDSrelated lymphomas: pathogenetic and histogenetic implications. Leuk Lymphoma 1998; 31: 39-46.
40. Fais F, Gaidano G, Capello D, et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphoma. Leukemia 1999; 13: 1093-9.
41. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, andCD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001; 97: 744-51.
42. Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003; 101: 4115-21.
43. Chadburn A, Hyjek E, Mathew S, et al. KSHVpositive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28: 1401-16.
44. Huang Q, Chang KL, Gaal K, Arber DA. Primary effusion lymphoma with subsequent development of a small bowel mass in a HIV-seropositive patient: a case report and literature review. Am J Surg Pathol 2002; 26: 1363-7.
45. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus- related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease, Blood 2002; 99: 2331-6.
46. Morassut S, Vaccher E, Balestrieri L, et al. HIVassociated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients, Radiology 1997; 205: 459-63.
47. Nakatsuka S, Yao M, Hoshida Y, et al. Pyothoraxassociated lymphoma: a review of 106 cases. J Clin Oncol 2002; 20: 4255-60.
48. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987-94.
49. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143: 265-73.
50. Valencia ME, Martinez P, Moreno V, Laguna F, Lahoz JG. AIDS-related body cavity-based lymphomas, herpesvirus-8 and HIV infection: a study of seven cases. AIDS 1999; 13: 2603-5.
51. Ascoli V, Lo Coco F, Torelli G, et al. Human herpesvirus 8-associated primary effusion lymphoma in HIVpatients:a clinicopidemiologic variant resembling classic Kaposi’s sarcoma, Haematologica 2002; 87: 339-43.
52. Simonelli C, Tedeschi R, Gloghini A, et al. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infec Dis 2005; 40: 1022-7.
53. Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998; 57: 266.
54. Hocqueloux L, Agblika F, Oksenhendler E, Molina JM Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15: 280-2.
55. Boulanger E, Daniel MT, Agbalika F, Oksenhend E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003; 73: 143-8.
56. Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006; 83: 328-30.
57. Klepfish A, Sarid R, Shtalrid M, et al. Primary effusion lymphoma (PEL) in HIV-negative patients - a distinct clinical entity. Leuk Lymphoma 2001; 41: 439-43.
58. Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005; 19: 473-6.
59. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006; 17: 1849-50.
60. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16: 569-96.
61. Dewan MZ, Terunuma H, Toi M, et al. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci 2006; 97: 1381-7.